About
Checkpoint Inhibitor
Areas of Focus
Categories
Small Molecule PharmaceuticalBoston & New England
Team (31)
Adam D. Levy
Chief Financial Officer
Acrivon Therapeutics
executive
Bruce Close
Quality and Compliance
Acrivon Therapeutics
team_member
Charles (Chuck) Baum
Director
Acrivon Therapeutics
team_member
Christina Scherer
Early Program Management
Acrivon Therapeutics
team_member
David Berman
Professor and Chair, Department of Pathology and Molecular Medicine, Queens University
Acrivon Therapeutics
board_chair
David Proia
Biology and Drug Discovery
Acrivon Therapeutics
team_member
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
2
As Collaborator
1
Total Enrollment
486
By Phase
PHASE1: 1PHASE2: 2
By Status
RECRUITING: 3
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2021
2022
2023
2024
2025
2026
2027
2028
2029
Today
Hover over trial bars to see details
Recent Trials
NCT06667141Lead Sponsor
Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors
PHASE1Recruiting
90 participants
Started: Oct 8, 2024 · Completed: Dec 12, 2026
NCT06597565Collaborator
A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC
PHASE2Recruiting
43 participants
Started: Sep 25, 2024 · Completed: Aug 23, 2028
NCT05548296Lead Sponsor
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
PHASE2Recruiting
353 participants
Started: Aug 29, 2022 · Completed: Apr 30, 2027
Locations (1)
Headquarters
Watertown, MA, United States
Map
Loading map...